These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18399014)

  • 1. Revised package insert for atazanavir.
    Sax PE
    AIDS Clin Care; 2008 Mar; 20(3):23. PubMed ID: 18399014
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA notifications. Revised atazanavir package insert.
    AIDS Alert; 2008 Mar; 23(3):35-6. PubMed ID: 18661642
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 6. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA notifications. Atazanavir capsule label is updated for pediatric patients.
    AIDS Alert; 2008 May; 23(5):59-60. PubMed ID: 18637262
    [No Abstract]   [Full Text] [Related]  

  • 8. Atazanavir in children.
    Prescrire Int; 2011; 20(118):177. PubMed ID: 21751749
    [No Abstract]   [Full Text] [Related]  

  • 9. Does atazanavir cause lipodystrophy?
    Gazzard BG; Moyle G
    J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urolithiasis in HIV-positive patients treated with atazanavir.
    Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
    Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065
    [No Abstract]   [Full Text] [Related]  

  • 12. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B
    GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
    [No Abstract]   [Full Text] [Related]  

  • 13. Boosted Reyataz: 48-week results.
    Huff B
    GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
    [No Abstract]   [Full Text] [Related]  

  • 14. A new protease inhibitor from Bristol-Myers Squibb.
    TreatmentUpdate; 2001; 12(12):5. PubMed ID: 11570092
    [No Abstract]   [Full Text] [Related]  

  • 15. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
    Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
    AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA notifications. Updates made to Reyataz package insert.
    AIDS Alert; 2008 Oct; 23(10):116-7. PubMed ID: 18935687
    [No Abstract]   [Full Text] [Related]  

  • 17. New protease inhibitor atazanavir (Reyataz) approved.
    AIDS Treat News; 2003 Jun; (392):3. PubMed ID: 12913956
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 19. Atazanavir background documents available.
    AIDS Treat News; 2003 May; (391):3. PubMed ID: 12866495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMS-232632, a new protease inhibitor, is taken once daily.
    Gaylord G
    Posit Living; 2000 Jul; 9(6):22. PubMed ID: 12492017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.